La Roche Posay Effaclar Lotion Astringente 200ml for Oily Skin 200ml
₦8,700.00
Effaclar Astringent Lotion is a daily facial toner suitable for oily to acne-prone skin. Formulated with micro-exfoliating (LHA), this toner smoothes and refines the skin’s texture and unblocks and tightens pores. Enlarged pores appear reduced.
This light, micro-exfoliating astringent lotion spreads easily on the face, leaving skin feeling refreshed.Perfect to use as part of your skincare routine.
Out of stock
Sorry, due to limited stock, La Roche Posay Effaclar Lotion Astringente 200ml for Oily Skin 200ml is restricted to 6 per customer. This restriction would be lifted once we restock.INGREDIENTS La Roche-Posay Effaclar Astringent Lotion follows a strict formulation charter and stringent clinical testing for efficacy and safety, even on sensitive skin. Effaclar Astringent Lotion is formulated with Lipo-Hydroxy Acid (LHA) to exfoliate skin, refine skin texture, unblock and tighten pores. Full Ingredients: Aqua/Water, Alcohol Denat, Glycerin, Sodium Citrate, Propylene Glycol, Peg-60 Hydrogenated Castor Oil, Disodium Edta, Capryloyl Salicylic Acid, Citric Acid, Salicylic Acid, Parfum/Fragrance APPPLICATION
How to apply Effaclar Astringent Lotion for oily and acne-prone skin:
- STEP 1: Cleanse skin using the Effaclar Purifying Gel Cleanser. Pat skin gently to dry.
- STEP 2: Apply a small amount of Effaclar Astringent Lotion to a cotton pad/ball.
- STEP 3: Gently press the face toner into skin using the cotton pad/ball. Can be used in the morning and/or evening. Avoid eye area.
To complete your anti-acne skincare routine, moisturize the skin with Effaclar Duo(+) Anti-Acne Moisturizer to fight pimples and shine, while providing 24-hour hydration. Follow up with Anthelios Ultra Fluid Face Lotion SPF 50+ sunscreen for daily sun protection.
Weight | 0.224 kg |
---|---|
Ingredients | Salicylic Acid |
Specific Concerns | Acne & Blemishes |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.